Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
about
Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum ComplexesAn integrated view of cisplatin-induced nephrotoxicity and ototoxicityPerceived Stress Levels, Chemotherapy, Radiation Treatment and Tumor Characteristics Are Associated with a Persistent Increased Frequency of Somatic Chromosomal Instability in Women Diagnosed with Breast Cancer: A One Year Longitudinal StudyIdentification of cisplatin-binding proteins using agarose conjugates of platinum compoundsIn vitro ovarian tumor growth and treatment response dynamics visualized with time-lapse OCT imaging.Pharmacodynamic model for chemotherapy-induced anemia in rats.Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatinHarnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacyCisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.Unusual DNA binding modes for metal anticancer complexes.Nanocarriers for delivery of platinum anticancer drugs.Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapyRadiosensitizers in cervical cancer. Cisplatin and beyond.Carboplatin pharmacokinetics in a patient receiving hemodialysis.Benzene-poly-carboxylic acid complex, a novel anti-cancer agent induces apoptosis in human breast cancer cells.Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacySteroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin.Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells.Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer.In vitro anticancer activity of cis-diammineplatinum(II) complexes with β-diketonate leaving group ligandsAnalysis of the cytotoxic activity of carboplatin and gemcitabine combination.Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacyCholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicityOn the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyOvercoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapyCisplatin/carboplatin cross-resistance in ovarian cancerSystemic therapy strategies for head-neck carcinomas: Current statusDNA interstrand crosslink repair and cancer.Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin.A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive ovarian carcinoma cell lines.Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell linesNon-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells
P2860
Q24289008-8FBD1F46-2094-4B58-9C3D-BCE37A8F3AEDQ28080615-69248EF2-5E64-406A-949B-94DA50F34957Q28383479-FB8216C8-B9EB-4F5B-9BE4-64C0BF9A39D5Q28533598-91C548F2-87A2-42D5-B1C4-14D59916AB15Q30493602-1684C5AC-30E9-473E-8B43-0DD486ED678BQ33376775-F63153F8-9F34-4885-B764-BF4877E4F13AQ33488335-C9BB5FA8-EBEF-4BD3-8254-A54FFA6E0185Q33564927-EBD6E21F-E35F-4712-98AA-03D4119F0865Q34005179-DC682DDD-B75F-463B-81DA-695BD3B078A1Q34009832-4919F815-774E-4E22-9B53-570F2AC7BB23Q34071185-FCF14C1D-8A8D-452E-AA82-811D3F4EB119Q34338695-935C7285-EA9C-4C98-B9E1-8BDC4696A01BQ34368410-30A66CA2-F86F-4FD3-9DBD-FB9CC3CD4858Q34640816-D7EC9379-16FC-4D56-8CA7-740D2A13D239Q34684307-E02A8876-C912-40B7-B33B-3A2DD35912ABQ35064102-E71A2AE5-4516-4449-AD1E-929E2CC465D1Q35093497-82CFC44B-FD39-4608-93AA-C799AD9FB967Q35099987-0C5ABFE0-7647-45C3-8FAE-98DF0BFCDAD1Q35173143-7B19C499-0F0B-4C45-AA09-0F2B53D16E3EQ35747835-61964B4D-E5B3-43D6-9E88-F8BE7389DF09Q35818950-240B32C5-9B50-4434-A381-1C417D865240Q35977254-896F5F1F-ACD3-480B-80AE-3097078CC424Q35978030-CF5697D8-4AFF-49EF-AF76-D06EDF6D0BC6Q35981405-EE38A86E-92C8-4FBE-9FD6-330AB09DC5ACQ35997145-C61663F5-E15B-4395-A04A-049551798AB6Q36032615-1F3F129E-3EC7-45AB-A913-7A97511EC437Q36035896-2FF0E222-506A-4208-BE97-5BC56C74359CQ36070256-A93782AF-DAA0-4A11-AF77-BFCE89F1801BQ36094353-7FE0B397-BAFD-4D16-A824-4635EE2F8937Q36107216-64B6ED50-1A55-4B15-8B00-11ACB23CE093Q36294083-4FDACE2B-CFE5-4A7F-B8C1-EA43915D0A3AQ36431475-93CFEBB7-0C2A-4158-AF81-DFD2213B00C0Q36467911-494925F4-C3E2-45A3-A108-2C6F1DC02BF5Q36529843-F0CCD45A-07DD-4A5E-8508-FB035B24FCAFQ36576047-1C5E8C29-F8CA-419C-B99D-8AEF17137F4CQ36643776-2ADF0B67-FDB6-4DF7-8ED5-896CACACB1E0Q36785185-619846AE-715A-44DA-9B15-B778B290A834Q36787695-BDC18E43-04A5-4782-AC51-B782C881033AQ36880024-6568698E-00D7-4814-9FDA-F9A84BB8A349Q36985163-649BEEDE-D8C2-465C-8D56-0E4E7C8D508D
P2860
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
description
1986 nî lūn-bûn
@nan
1986年の論文
@ja
1986年論文
@yue
1986年論文
@zh-hant
1986年論文
@zh-hk
1986年論文
@zh-mo
1986年論文
@zh-tw
1986年论文
@wuu
1986年论文
@zh
1986年论文
@zh-cn
name
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@en
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@nl
type
label
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@en
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@nl
prefLabel
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@en
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@nl
P2093
P1433
P1476
Mechanism of cytotoxicity of a ...... of their interaction with DNA.
@en
P2093
P304
P407
P433
P577
1986-04-01T00:00:00Z